Ando, Shotaro <br/><br/>
Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.  [electronic resource] 

 -  Oncotarget  Nov 2016 
 - 76793-76805 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.12529  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Biomarkers<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>Epstein-Barr Virus Infections--complications<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Gene Expression Regulation, Viral--drug effects<br/>Herpesvirus 4, Human--genetics<br/>Humans<br/>Janus Kinase 3--metabolism<br/>Killer Cells, Natural--drug effects<br/>Lymphocyte Activation--drug effects<br/>Lymphoma, T-Cell--etiology<br/>Mice<br/>Piperidines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyrimidines--pharmacology<br/>Pyrroles--pharmacology<br/>STAT5 Transcription Factor--metabolism<br/>T-Lymphocytes--drug effects<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays